

**Studies of Immune Biology of
The Common Marmoset:
A Novel Non-Human Primate Transplant Model.**

Dr Shilpanjali Prasad, MBBS, FRACP

(Shilpanjali Jesudason)

**Transplantation Immunology Laboratory
The Queen Elizabeth Hospital
Department of Medicine, Discipline of Medicine,
University of Adelaide**

Submitted in fulfilment of the
Degree of Doctor of Philosophy,
University of Adelaide,
May 2009

TABLE OF CONTENTS

Thesis Abstract	7
Declarations	9
Presentations and Awards	10
Acknowledgements, Funding and Addendum	11
CHAPTER 1: INTRODUCTION	15
1. Seeking Transplant Tolerance	15
2. Dendritic Cell Biology	17
2.1 Introduction	17
2.2 DC Ontogeny and Precursors	19
2.3 Classification of DC Subsets	22
2.3.1 Murine DC	22
2.3.2 Human DC	26
2.3.3 <i>In-vitro</i> Propagated DC	31
3. Dendritic Cells in Transplantation and Tolerance	37
3.1 DC and Allo-recognition	37
3.2 DC and Tolerance Induction	38
3.2.1 Generation of Tolerogenic DC	38
3.2.3 Recipient Pre-conditioning with Tolerogenic DC	47
3.2.4 Targeting Recipient DC <i>In-vivo</i>	51
3.2.5 DC-induced Regulatory T-cell Generation	51
3.2.6 <i>In-vivo</i> Expansion of DC	52
4. Non-Human Primates in Transplant Tolerance Research	54
4.1 Introduction	54
4.2 The Common Marmoset: A Novel Transplant Model	57
4.3 Transplant Tolerance Strategies Developed in NHP Models	60
4.3.1 T-cell Depletion	60
4.3.2 Deoxyspergualin and Analogues	61
4.3.3 Co-stimulation Blockade	63
4.3.4 Mixed Chimerism Induction	67
4.3.5 Adoptive Cellular Therapies	69
4.3.6 Transplant Tolerance Strategies in NHP: Conclusions	70
4.4 Non-human Primate Dendritic Cells	71
4.4.2 Identification and Characterisation of NHP DC	71

4.4.2 DC-based Immune Modification in Non-Human Primate Models	73
5. Thesis Aims and Hypotheses	76
CHAPTER 2: MATERIALS AND METHODS	77
1. Animals	77
1.1 Marmoset Colony Maintenance	77
1.2 Peripheral Blood Sampling	78
2. Buffers, Medium and Solutions	79
3. Gene Studies	80
3.1 DNA extraction	80
3.2 <i>Caja</i> -DRB Gene Sequencing Method	80
3.2.1 Primary PCR	80
3.2.2 Exon 2 Template Fluorescent Dye Terminator Cycle Sequencing	81
3.3 Sequencing of Marmoset RelB Gene	82
3.3.1 RNA Extraction and Reverse Transcription	82
3.3.2 Real-time PCR	82
4. Cell Isolation Protocols	83
4.1 Peripheral Blood Mononuclear Cell Isolation	83
4.2 Isolation of CD14 ⁺ Monocytes from PBMC using Automacs [®]	83
4.3 Isolation of CD14 ⁺ Monocytes from Whole Blood Using Automacs [®]	84
4.4 Isolation of CD14 ⁺ Monocytes from PBMC Via Plastic Adherence	84
4.5 Isolation of CD34 ⁺ Peripheral Blood Stem Cells	85
5. <i>In-vitro</i> DC propagation	85
5.1 Generation of Monocyte-derived Dendritic Cells (MoDC)	85
5.2 Generation of Haematopoietic Progenitor-Derived DC (HPDC)	86
6. Mixed Leukocyte Reaction (MLR)	86
6.1 Two-way MLR	86
6.2 One-way MLR	87
6.3 Dendritic Cell MLR	87
7. Morphological Assessment of Cells	88
7.1 Light Microscopy	88
7.2 Transmission Electron Microscopy	88

8. Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS)	88
8.1 Monoclonal Antibodies	88
8.2 Sample Preparation and Analysis	89
8.3 Two and Three Colour Labelling for Dendritic Cell Identification	89
8.3.1 Compensation Samples	89
8.3.2 Monocyte, Stem Cell and DC Identification	90
8.4 FACS of Myeloid DC from Whole Blood	90
8.5 FITC-Dextran Uptake Assay	91
8.6 Intracellular Flow Cytometric Staining For Stat-6 Signalling	91
9. Allogeneic PBMC-Stimulated IFN-γ Production	92
10. Blood Group Typing and Cross-match	93
11. Manufacturers	94
CHAPTER 3: SEQUENCE-BASED GENOTYPING OF MARMOSET MHC DRB GENES	96
1. Introduction	96
2. Methods	98
3. Results	98
3.1 <i>Caja</i> -DRB genotyping	98
3.2 Mixed Lymphocyte Reactions	103
4. Discussion	106
5. Addendum	111
5.1 Additional Data Regarding Marmoset MHC	111
5.2 Sequencing of Other <i>Caja</i> -MHC Loci	111
CHAPTER 4: <i>IN-VITRO</i> PROPAGATION OF MARMOSET DC FROM BLOOD PRECURSORS	113
1. Introduction	113
2. Methods	115
3. Results	115
3.1 G-CSF Mobilises Marmoset Monocytes and CD34 ⁺ Cells	115
3.2 Human IL-4 Leads to Signalling Via STAT-6	118
3.3 Marmoset Monocyte-Derived DC	119

3.3.1 Selection of Marmoset Monocytes for DC Differentiation	119
3.3.2 G-CSF Mobilised MoDC Have Typical DC Morphology	120
3.3.3 Marmoset MoDC Have an Immature Phenotype And Are Maturation Resistant	123
3.4 Haematopoietic Precursor-Derived DC	132
3.4.1 Culture in Early-acting Cytokines Expands a Myeloid HP Population	132
3.4.2 HPDC Have a Semi-Mature Phenotype	136
3.5 RelB mRNA Expression is Variably Up-regulated in Marmoset DC	140
4. Discussion	143
CHAPTER 5: PROPAGATION OF MARMOSET <i>IN-VIVO</i> DC USING FLT3-LIGAND	156
1. Introduction	157
2. Methods	158
2.1 FLT3-L Mobilisation	158
2.2 Strategy for Identification and Isolation of Marmoset Myeloid DC	159
2.3 Cell Culture and MLR	159
3. Results	161
3.1 Safety and Tolerability	161
3.2 FLT3-L Increases Circulating Leukocyte and CD34 ⁺ Stem Cell Populations	161
3.3 FLT3-L Mobilises Putative Peripheral Blood Myeloid DC	165
3.4 FLT3-L mobilised Lin ⁻ ClassII ⁺ CD11c ⁻ cells acquire CD11c in culture	171
3.5 Identification of Lin ⁻ ClassII ⁺ CD123 ⁺ Cells in FLT3-L Mobilised Marmosets	172
3.6 Identification of Lin ⁻ ClassII ⁺ BDCA2 ⁺ Cells in FLT3-L Mobilised Marmosets	174
4. Discussion	176
CHAPTER 6: INFUSION OF DONOR-DERIVED IMMATURE DC IN MARMOSET RECIPIENTS	181
1. Introduction	181
2. Methods	182
2.1 Donor and Recipient Selection	182
2.2 Generation and Infusion of MoDC	184
2.3 MLR	184
2.4 IFN- γ ELISpot Assay	184
3. Results	185
3.1 Safety of DC Immunotherapy	185
3.2 Changes in Anti-Donor Immune Responses	185

4. Discussion	191
CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS	196
1. Summary and Conclusions	196
2. Future Directions	199
2.1 Planned Studies For Further Evaluation Of Marmoset DC	199
2.2 Planned Studies Of DC Immunotherapy In Marmoset Organ Transplant	200
REFERENCES	202
APPENDIX 1: Publications	223

THESIS ABSTRACT

Donor-specific immune tolerance is a highly desirable goal in clinical transplantation. Dendritic cells (DC) are potent immune system regulators, and promoting both anti-donor immunity and immune tolerance. DC are therefore an important target for potential tolerance-inducing therapies, which must be validated in non-human primate models before clinical trials. The common marmoset is a small, New World primate which our group is developing as a novel transplant model. The scope of this thesis involves the development of methodology and characterisation of critical aspects of marmoset immune biology pertinent to transplantation and DC immunotherapy.

Chapter 1 discusses the context of this thesis and contains a comprehensive literature review.

Chapter 2 outlines methodology and materials utilised in this thesis.

Chapter 3 describes a new technique for genotyping marmoset major histocompatibility complex (MHC) Class II DRB genes, to facilitate choosing mismatched donor and recipient animals for transplant studies. Genotype-based matching was predictive of *in-vitro* immune reactivity, and therefore validated as a method for selecting immunologically disparate animal pairs. Two new alleles were also identified. This work has given rise to two publications, and the methodology subsequently extended to marmoset MHC Class I and other Class II genes by others in our group.

Chapter 4 describes the first-ever studies of propagation of marmoset DC *in-vitro* from peripheral blood DC precursors (monocytes and stem cells) mobilised by the growth factor G-CSF. These methods enabled large-scale DC production from small volumes of peripheral blood. Marmoset DC were characterised extensively by morphology, phenotype and function, with many similarities to human and NHP DC. As with all animal models, specific differences

were also identified. In particular, marmoset monocyte-derived DC were maturation-resistant, whereas stem-cell derived DC were semi-mature. This work establishes that marmoset DC exist within the paradigm of human and NHP DC systems, and is therefore a feasible model for DC-based tolerance studies.

Chapter 5 describes for the first time the *in-vivo* propagation of marmoset DC following treatment with the growth factor FLT3-Ligand. A three-colour flow cytometry strategy for identifying and sorting marmoset putative peripheral blood myeloid DC was validated. The rare myeloid DC population was expanded massively by FLT3-Ligand, and could be isolated in numbers sufficient for therapeutic use. These DC had typical myeloid DC morphology and were capable of immune stimulation *in-vitro*. In addition, new markers for plasmacytoid DC were evaluated. This work forms the basis for ongoing studies of *in-vivo* marmoset DC.

Chapter 6 describes the culmination of the studies outlined in earlier chapters, with the first-ever studies of DC immunotherapy in marmoset monkeys. Three donor and recipient pairs were chosen on the basis of MHC genotype mismatch. Donor animals were treated with G-CSF and immature monocyte-derived DC propagated *in-vitro*. Recipient animals were treated with intravenous infusion of unmodified immature donor DC, and immune responses monitored. Two animals exhibited reduction in anti-donor (and third party) immune responses, whereas one animal was initially sensitized to donor cells. These preliminary studies establish the feasibility of DC-based immunotherapy in this model, and demonstrate that DC-induced immune modification can occur and be successfully monitored.

Thus, the work presented in this thesis creates a platform from which future studies of DC-based immune tolerance strategies can be developed in this novel transplant model.

DECLARATIONS

I declare that this thesis contains no material which has been accepted for the award of any other degree or diploma in any university or tertiary institution to Shilpanjali Prasad and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time. I acknowledge that the copyright of published works contained within this thesis (as listed below) resides with the copyright holders of those works. Permission to reproduce has been obtained from the publishers as shown below.

1. Prasad S, Humphreys I, Kireta S, Gilchrist RB, Bardy P, Russ GR, Coates PT. MHC Class II DRB genotyping is highly predictive of *in-vitro* alloreactivity in the common marmoset. *J Immunol Methods*. 2006 Jul 31;314(1-2):153-63. (Publisher: ELSEVIER; License Agreement Date 27.10.08; Number 2056931094502)
2. Prasad S, Humphreys I, Kireta S, et al. The common marmoset as a novel preclinical transplant model: identification of new MHC class II DRB alleles and prediction of *in-vitro* alloreactivity. *Tissue Antigens* 2007; 69 Suppl 1: 72-75. (Publisher: WILEY-BLACKWELL; permission not required for reproduction of own article in self-edited publication).

PRESENTATIONS AND AWARDS

- 2008 Australasian Society for Immunology, Annual Scientific Meeting, Canberra (Poster)
- 2008 XXII International Congress of The Transplantation Society, Sydney (ePoster)
Recipient of TSANZ Young Investigators Award
- 2008 Postgraduate Research Expo, Faculty of Health Sciences, University of Adelaide, Adelaide (Poster)
- 2007 TQEH Research Day, Adelaide (Oral Presentation)
Winner, Best Higher Degree Presentation (Medical)
- 2007 Australia and New Zealand Society of Nephrology, Annual Scientific Meeting, Gold Coast (Oral Presentation)
Finalist, Young Investigators Award
- 2007 World Congress of Nephrology, Rio de Janeiro (Poster)
- 2007 Transplantation Society of Australia and New Zealand, Annual Scientific Meeting, Canberra (Mini-Oral Presentation)
- 2007 Australasian Society for Immunology, Annual Scientific Meeting, Sydney (Oral Presentation)
- 2006 Transplantation Society of Australia and New Zealand, Annual Scientific Meeting, Canberra (Oral Presentation)
Recipient of TSANZ Young Investigators Award
- 2006 TQEH Research Day, Adelaide (Oral Presentation)
- 2005 14th International HLA and Immunogenetics Workshop (IHIWS), Melbourne (Oral Presentation)
- 2005 Australasian Society for Immunology, Annual Scientific Meeting, Melbourne (Poster)
- 2004 Australasian Society for Immunology, Annual Scientific Meeting, Adelaide (Oral Presentation)
- 2004 Australasian and South East Asian Tissue Typing Association (ASEATTA) Annual Meeting, Sydney (Poster)
- 2004 TQEH Research Day, Adelaide (Poster)
- 2004 Australia and New Zealand Society of Nephrology, Annual Scientific Meeting, Adelaide (Poster)

ACKNOWLEDGEMENTS

Firstly, I sincerely thank my supervisors, A/Prof Toby Coates and Professor Graeme Russ for their invaluable mentorship. I have greatly respected and admired Toby's boundless enthusiasm, brilliant thinking, infectious love of the thrills of Science, eternal optimism (and did I mention enthusiasm?) It has been a privilege to work with him. I thank Graeme for the many opportunities he has facilitated on my behalf, and his decisive and always insightful opinions. I am also deeply grateful to them for the flexibility and autonomy granted to me over the last five years, which has enabled balancing the demands of a PhD with that of a family.

The rock and mainstay of our laboratory, Svjetlana Kireta, taught me everything and helped me with everything. She was never too busy, and always ready to assist, teach, and listen. She is, as we have often gratefully declared, "an absolute legend". Thank you for your special friendship.

I am also indebted to all the staff and students of the TIL during my tenure, especially Dr Ravi Krishnan, Emma Leedham, Julie Johnston, Austin Milton, Clyde Milner, Chris Drogemuller, Darling Rojas, Natasha Rogers, Dieu Dang, Boris Fedoric, Wai Lim and Ashley Newland, for practical assistance, teaching, helpful discussions, insights and thoughtful feedback. Thank you for providing a friendly, accommodating and generous environment in which to develop skills and learn. The staff of the TQEH Animal House also require particular mention for their assistance with all aspects of animal maintenance, for patiently teaching me to handle marmosets and take blood samples and for helping me on many weekend mornings.

I would like to thank Ian Humphries (Australian Red Cross Blood Service Tissue Typing Laboratory, Adelaide) for his invaluable assistance with sequencing and analysis performed in Chapter 3, Chris Drogemuller (TQEH) for guidance with RelB sequence analysis, John Breal for electron microscopy assistance, Dr Ian Lewis (Department of Haematology, Royal Adelaide Hospital) for facilitating access to the Allogeneic Stem Cell Transplant Program, and the donors for providing blood samples.

I have been blessed to have a magnificent family and in-laws who have been my utterly reliable back-up on innumerable occasions, acted as surrogate mothers to my children, and given moral support and encouragement at every step. Thank you all for everything; this would not have been remotely achievable without your continuous help.

To my beautiful precious children, Daniel (born between Chapters 3 and 4) and Sonali (born between Chapters 6 and 7), you have without doubt been the most important thing I have produced during these years. I hope one day you might read this thesis, and see what I was up to when you were babies. Failing that, I hope at least you don't attempt to use it as a dinner plate, embellish it with your art work, or test its ability to float.

And finally, to my husband David. Your unwavering support of me and wonderful devotion to our family has made all this possible, and to you I dedicate this thesis.

FUNDING

This thesis was financially supported by a National Health and Medical Research Council (NHMRC) of Australia Postgraduate Medical Research Scholarship awarded to Shilpanjali Prasad and an NHMRC Project Grant awarded to A/Prof P.T.H. Coates (Grant Number 339374).

ADDENDUM

Please note that references 232,236, 237, 239, 240 and 241 have been withdrawn by the authors. This came to my attention following the submission of this thesis. This is a body of work from the University of Alabama (Professor Judy Thomas) relating to the STEALTH protocol for tolerance induction in rhesus monkeys. The data relating to graft and animal survival in these studies have been found to be inaccurate. Full details may be obtained at http://ori.dhhs.gov/misconduct/cases/Thomas_Judith.shtml and http://ori.dhhs.gov/misconduct/cases/Contreras_Juan_Luis.shtml.

I have retained text in Chapter 1 relating to these studies of non-human primate transplant tolerance induction, because at the time of publication and in the years following they were important studies that related to other studies in this area and seemingly advanced the field. Therefore the existence of these studies remains relevant, despite the fact the data is now believed to be misleading. However, I have clearly identified discussion relating to withdrawn publications.

ABBREVIATIONS

AA – alternatively activated DC

APC – antigen presenting cell

BDCA – blood dendritic cell antigen

BM- bone marrow

Caja – *Callithrix jacchus*

CD – cluster of differentiation

CD40L – CD40 ligand

cDC – conventional DC

CpG – cytosine-guanine oligonucleotide

CTLA-4 – cytotoxic T lymphocyte associated antigen-4

DC – dendritic cell

DC-SIGN - DC-specific intercellular adhesion molecule [ICAM]-3 grabbing non-integrin

DNA – deoxyribonucleic acid

DSG - Deoxyspergualin

EDTA – ethylenediamine tetra acetic acid

ELISpot – enzyme linked immuno-spot assay

FCS – foetal calf serum

FLT3 – fms-like tyrosine kinase 3

FLT3-L – FLT3-ligand

FOXP3 – forkhead box protein 3

G-CSF –granulocyte colony stimulating factor

GM-CSF – granulocyte-macrophage colony stimulating factor

HLA – human leukocyte antigen

HP – haematopoietic precursor

HPDC – DC cultured from haematopoietic precursor cells

iDC – immature DC

IDO – indoleamine 2,3-dioxygenase

IFN – interferon

Ig - immunoglobulin

IL- interleukin

Lin - lineage

LPS - lipopolysaccharide
MDC – myeloid DC
MHC – major histocompatibility complex
MLR – mixed lymphocyte (leukocyte) reaction
MoDC – monocyte-derived DC
NF – nuclear factor
NHP – non-human primate
NK – natural killer
PB – peripheral blood
PBS – phosphate buffered saline
PBMC – peripheral blood mononuclear cell
PCR – polymerase chain reaction
PDC – plasmacytoid DC
RNA – ribonucleic acid
RPMI – Roswell Park Memorial Institute medium
SCF – stem cell factor
Treg – regulatory T-cell
TLR – toll-like receptor
TNF – tumour necrosis factor
TPO – thrombopoietin
TQEH – The Queen Elizabeth Hospital
WCC – White cell count